Skip to main content Back to Top
Advertisement

5/17/2021

Telmisartan Tablets

Products Affected - Description

    • Telmisartan tablet, Hikma, 40 mg, bottle, 30 count, NDC 00054-0543-18
    • Telmisartan tablet, Solco Healthcare US, 20 mg, bottle, 30 count, NDC 43541-0283-03
    • Telmisartan tablet, Solco Healthcare US, 40 mg, bottle, 30 count, NDC 43541-0284-03
    • Telmisartan tablet, Solco Healthcare US, 80 mg, bottle, 30 count, NDC 43541-0285-03
    • Telmisartan tablet, Torrent, 20 mg, bottle, 30 count, NDC 13668-0156-30 - discontinued
    • Telmisartan tablet, Torrent, 20 mg, container, 30 count, NDC 13668-0156-72 - discontinued
    • Telmisartan tablet, Torrent, 40 mg, bottle, 30 count, NDC 13668-0157-30 - discontinued
    • Telmisartan tablet, Torrent, 40 mg, container, 30 count, NDC 13668-0157-72 - discontinued
    • Telmisartan tablet, Torrent, 80 mg, bottle, 30 count, NDC 13668-0158-30 - discontinued
    • Telmisartan tablet, Torrent, 80 mg, container, 30 count, NDC 13668-0158-72 - discontinued

Reason for the Shortage

    • Alembic has telmisartan available.
    • Amneal Pharmaceuticals discontinued telmisartan tablets.
    • Aurobindo refuses to provide information.
    • Cadista discontinued telmisartan tablets.
    • Camber Pharmaceuticals discontinued telmisartan tablets.
    • Glenmark Pharmaceuticals has updated NDC numbers for telmisartan.
    • Hikma is not marketing telmisartan tablets.
    • Mylan has telmisartan tablets available.
    • Sandoz discontinued telmisartan tablets.
    • Solco Healthcare did not provide a reason for the shortage.
    • Torrent discontinued telmisartan tablets.
    • Zydus has telmisartan tablets available.

Available Products

    • Micardis tablet, Boehringer Ingelheim, 20 mg, bottle, 30 count, NDC 00597-0039-37
    • Micardis tablet, Boehringer Ingelheim, 40 mg, bottle, 30 count, NDC 00597-0040-37
    • Micardis tablet, Boehringer Ingelheim, 80 mg, bottle, 30 count, NDC 00597-0041-37
    • Telmisartan tablet, Alembic, 20 mg, bottle, 30 count, NDC 62332-087-30
    • Telmisartan tablet, Alembic, 40 mg, bottle, 30 count, NDC 62332-088-30
    • Telmisartan tablet, Alembic, 80 mg, bottle, 30 count, NDC 62332-089-30
    • Telmisartan tablet, Glenmark, 20 mg, bottle, 30 count, NDC 68462-0199-30
    • Telmisartan tablet, Glenmark, 40 mg, bottle, 30 count, NDC 68462-0200-30
    • Telmisartan tablet, Glenmark, 80 mg, bottle, 30 count, NDC 68462-0201-30
    • Telmisartan tablet, Mylan, 20 mg, bottle, 30 count, NDC 00378-2920-93
    • Telmisartan tablet, Mylan, 20 mg, bottle, 90 count, NDC 00378-2920-77
    • Telmisartan tablet, Mylan, 40 mg, bottle, 30 count, NDC 00378-2921-93
    • Telmisartan tablet, Mylan, 40 mg, bottle, 90 count, NDC 00378-2921-77
    • Telmisartan tablet, Mylan, 80 mg, bottle, 30 count, NDC 00378-2922-93
    • Telmisartan tablet, Mylan, 80 mg, bottle, 90 count, NDC 00378-2922-77
    • Telmisartan tablet, Zydus, 20 mg, bottle, 30 count, NDC 68382-0471-78
    • Telmisartan tablet, Zydus, 40 mg, bottle, 30 count, NDC 68382-0472-78
    • Telmisartan tablet, Zydus, 80 mg, bottle, 30 count, NDC 68382-0473-78

Estimated Resupply Dates

    • Solco has all preparations of telmisartan tablets on back order and the company cannot estimate a release date

Updated

Updated May 17, 2021 by Leslie Jensen, PharmD, Drug Information Specialist. Created October 23, 2019 by Rachael Freeman, PharmD, BCPS. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.